<DOC>
	<DOCNO>NCT01044706</DOCNO>
	<brief_summary>The objective study compare rate extent absorption bicalutamide 50 mg tablet ( test ) versus Casodex® ( reference ) , administer 1 x 50 mg tablet feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Bicalutamide 50 mg Tablet Casodex® 50 mg Tablet Healthy Subjects Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Male , nonsmoker , 18 year age old ; Capable consent ; BMI≥19.0 &lt; 30.0 kg/m2 . Clinically significant illness within 4 week prior administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive test hepatitis B , hepatitis C , HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . History significant alcohol abuse drug abuse within one year prior screen visit . Regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) . Use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction heparin , bicalutamide , related drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin . garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Difficulty swallow study medication . Use tobacco product 6 month precede drug administration . Any food allergy , intolerance , restriction special diet , opinion Medical SubInvestigator , could contraindicate subject 's participation study . A depot injection implant drug within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 300 mL whole blood within 30 day , 301 mL 500 mL whole blood within 45 day , 500 mL whole blood within 56 day prior drug administration .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Bioequivalency</keyword>
</DOC>